Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 16Smoldering Multiple Myeloma 2Recurrence 2Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1

Interventions

Dexamethasone 4iberdomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Lenalidomide 2Curcumin 2Calcium Dobesilate 2selinexor 1isatuximab 1daratumumab 1Resistance Training 1Propranolol 1Probiotics 1Docosahexaenoic Acids 1Dietary Fiber 1Diet, Plant-Based 1Diet, Mediterranean 1Blood Specimen Collection 1Behavior Therapy 1Adrenergic beta-Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Smoldering Multiple Myeloma × iberdomide × Clear all
NCT04776395 2026-06-01

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Emory University

Phase 2 Recruiting
68 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting
63 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡